IFN-λ Inhibits MIR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Aboulnasr, Fatma ^a   Hazari, Sidhartha ^a   Nayak, Satyam ^a   Chandra, Partha K ^a   Panigrahi, Rajesh ^a   Ferraris, Pauline ^a   Chava, Srinivas ^a   Kurt, Ramazan ^b   Song, Kyongsub ^a   Dash, Asha ^a   Balart, Luis A ^b   Garry, Robert F ^a   Wu, Tong ^a   Dash, Srikanta ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA 1 INTERFERON; GAMMA INTERFERON; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; JANUS KINASE; MICRORNA 122; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; JANUS KINASE 1; MICRORNA; MIRN122 MICRORNA, HUMAN; RIBAVIRIN; STAT2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; VIRUS RNA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE; GENE EXPRESSION; HEPATITIS C; INTERFERON SIMULATED GENE; NORTHERN BLOTTING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; HUMAN; LIVER CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGICAL FEEDBACK; TUMOR CELL LINE; VIROLOGY;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATOCYTE NUCLEAR FACTOR 4; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; JANUS KINASE 1; MICRORNAS; PHOSPHORYLATION; RIBAVIRIN; RNA, VIRAL; SIGNAL TRANSDUCTION; STAT2 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

EID: 84957109814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141655     Document Type: Article

References (44)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1:74-81. doi: 10.1111/j.1478-3231.2008.01934.x PMID: 19207969
2. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. doi: 10.1038/nrgastro.2010.100 PMID: 20628345
3. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013; 10(9):553-62. doi: 10.1038/nrgastro.2013.107 PMID: 23817321
4. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015; 385(9973):1124-35. doi: 10. 1016/S0140-6736(14)62401-6 PMID: 25687730
5. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368(20):1907-17. doi: 10.1056/NEJMra1213651 PMID: 23675659
6. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013; 33 Suppl 1:93-104. doi: 10.1111/liv.12076 PMID: 23286852
7. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 2015; 6:6422. doi: 10.1038/ncomms7422 PMID: 25740255
8. Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012; 142(4):790-5. doi: 10.1053/j.gastro.2011.12.057 PMID: 22248659
9. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014; 209(11):1700-4. doi: 10.1093/infdis/jit827 PMID: 24367041
10. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014; 124(8):3352-63. doi: 10. 1172/JCI75938 PMID: 24983321
11. Morgan TR, O'Brien TR. IL28B-genotype testing now and in the era of direct-Acting antiviral agents. Clin Gastroenterol Hepatol. 2011; 9(4):293-4. doi: 10.1016/j.cgh.2010.12.014 PMID: 21185399
12. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. doi: 10.1038/nature08463 PMID: 19759533
13. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol. 2014; 29(2):241-9. doi: 10.1111/jgh.12475 PMID: 24325405
14. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4):1338-45, 45 e1-7. doi: 10.1053/j.gastro.2009.12.056 PMID: 20060832
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. doi: 10.1038/nature08309 PMID: 19684573
16. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-Alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. doi: 10.1038/ng.447 PMID: 19749758
17. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-Alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. doi: 10.1038/ng.449 PMID: 19749757
18. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2):164-71. doi: 10.1038/ng.2521 PMID: 23291588
19. Donnelly RP, Dickensheets H, O'Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011; 32(9):443-50. doi: 10.1016/j.it.2011.07.002 PMID: 21820962
20. Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, et al. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One. 2012; 7(10):e44915. doi: 10.1371/journal.pone.0044915 PMID: 23071503
21. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327 (5962):198-201. doi: 10.1126/science.1178178 PMID: 19965718
22. Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS. Transcriptional regulation of IFN-?ambda genes in hepatitis C virus-infected hepatocytes via IRF-3.IRF-7.NF-kappaB complex. J Biol Chem. 2014; 289 (8):5310-9. doi: 10.1074/jbc.M113.536102 PMID: 24385435
23. Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, et al. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A. 2013; 110(19):7844-9. doi: 10.1073/pnas.1306138110 PMID: 23613588
24. Li ZY, Xi Y, Zhu WN, Zeng C, Zhang ZQ, Guo ZC, et al. Positive regulation of hepatic miR-122 expression by HNF4alpha. J Hepatol. 2011; 55(3):602-11. doi: 10.1016/j.jhep.2010.12.023 PMID: 21241755
25. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol. 2011; 55(2):289-98. doi: 10.1016/j.jhep.2010.11.019 PMID: 21147189
26. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008; 7(7):1109-15. PMID: 18698163
27. Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, et al. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol. 2014; 184(1):214-29. doi: 10.1016/j.ajpath. 2013.10.005 PMID: 24215913
28. Panigrahi R, Chandra PK, Ferraris P, Kurt R, Song K, Garry RF, et al. Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1. J Virol. 2015; 89(1):626-42. doi: 10.1128/JVI.02492-14 PMID: 25339775
29. Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, et al. Impaired expression of type I and type II interferon receptors in HCV-Associated chronic liver disease and liver cirrhosis. PLoS One. 2014; 9(9):e108616. doi: 10.1371/journal.pone.0108616 PMID: 25265476
30. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Foster TP, et al. Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J. 2010; 7:36. doi: 10.1186/1743-422X-7-36 PMID: 20149251
31. Redig AJ, Sassano A, Majchrzak-Kita B, Katsoulidis E, Liu H, Altman JK, et al. Activation of protein kinase C{eta} by type I interferons. J Biol Chem. 2009; 284(16):10301-14. doi: 10.1074/jbc. M807254200 PMID: 19211565
32. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-Activated protein kinases. J Virol. 2007; 81(14):7749-58. PMID: 17507495
33. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007; 449(7164):919-22. PMID: 17943132
34. Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology. 2010; 52(5):1702-12. doi: 10.1002/hep.23875 PMID: 21038412
35. Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, et al. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology. 2013; 58(5):1681-92. doi: 10.1002/hep.26514 PMID: 23703729
36. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011; 147 (6):1233-47. doi: 10.1016/j.cell.2011.10.043 PMID: 22153071
37. Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem. 2010; 285(30):22741-7. doi: 10.1074/jbc.R109.099556 PMID: 20457596
38. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-Alpha in vivo. Hepatology. 2011; 53(4):1154-63. doi: 10.1002/hep.24189 PMID: 21480323
39. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One. 2011; 6(7):e22200. doi: 10.1371/journal. pone.0022200 PMID: 21779393
40. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 1995; 14(7):1421-9. PMID: 7537214
41. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122(8):2871-83. doi: 10.1172/JCI63539 PMID: 22820288
42. Datta S, Hazari S, Chandra PK, Samara M, Poat B, Gunduz F, et al. Mechanism of HCV's resistance to IFN-Alpha in cell culture involves expression of functional IFN-Alpha receptor 1. Virol J. 2011; 8:351. doi: 10.1186/1743-422X-8-351 PMID: 21756311
43. Wang H, Gao B. MicroRNAs control hepatocarcinogenesis by regulating hepatocyte nuclear factor 4alpha-inflammatory signal feedback loops. Hepatology. 2014; 60(5):1466-8. doi: 10.1002/hep.27287 PMID: 24996014
44. Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015; 61(3):1066-79. doi: 10.1002/hep.27332 PMID: 25066777